Highlights
- •Circulating tumor DNA (ctDNA) has become a sensitive and specific biomarker to identify TNBC at early stage, monitoring of minimal residual disease, prognosis, and treatment response.
- •Standard treatment for patients with TNBC does not differ while the presence of ctDNA indicates high risk of recurrence. An adequate precision therapy has yet to be identified based on the status of ctDNA, for those with high risk of relapse (ie, ctDNA positivity), it may be benefit in treatment-escalation in the adjuvant therapy.
- •ctDNA has been used in management of precise therapy in on-going clinical trials.
Abstract
Triple-negative breast cancer is a sub-type of clinically and molecularly heterogeneous
malignant disease with a worse prognosis and earlier recurrence than HER2-amplified
or hormone-receptor positive breast cancer. Because of the lack of personalized therapy,
genetic information is essential to early diagnosing, identifying the high risk of
recurrence, guiding therapeutic management, and monitoring treatment efficiency. Circulating
tumor DNA (ctDNA) is a novel noninvasive, timely, and tumor specified biomarker that
reliably reflects the comprehensive tumor genetic profiles. Thus, it holds significant
expectations in personalized therapy, including accurate diagnosis, treatment monitoring,
and early detection of recurrence of TNBC. In this review, we summarize the results
from recent and ongoing ctDNA-based biomarker-driven clinical trials, with respect
to ctDNA analysis' predictive role, in adjuvant, neo-adjuvant, and metastatic settings.
Collectively, we anticipate that ctDNA will ultimately be integrated into the management
of TNBC to foster precise treatment.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dissecting the heterogeneity of triple-negative breast cancer.J Clin Oncol. 2012; 30: 1879-1887
- Triple-negative breast cancer comparison with canine mammary tumors from light microscopy to molecular pathology.Front Oncol. 2020; 10563779
- Cancers (Basel). brain metastases in HER2-positive breast cancer: current and novel treatment strategies.Cancers (Basel). 2021; 13: 2927
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol. 2008; 26: 1275-1281
- Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.Clin Cancer Res. 2020; 26: 2838-2848
- Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update.J Clin Oncol. 2018; 36: 2433-2443
- Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.Nat Rev Clin Oncol. 2018; 15: 577-586
- Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer.Clin Cancer Res. 2020; 26: 2556-2564
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.Ann Oncol. 2019; 30: 1804-1812
- Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer.J Clin Oncol. 2018; 36: 543-553
- Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study.J Clin Oncol. 2017; 35: 751-758
- Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol. 2014; 32: 579-586
- Les acides nucléiques du plasma sanguin chez l'Homme [French].C R Seances Soc Biol Fil. 1948; 142: 241-243
- Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res. 1977; 37: 646-650
- Neoplastic characteristics of the DNA found in the plasma of cancer patients.Oncology. 1989; 46: 318-322
- Soluble normal and mutated DNA sequences from single-copy genes in human blood.Cancer Epidemiol Biomarkers Prev. 1994; 3: 67-71
- Detection and quantification of mutations in the plasma of patients with colorectal tumors.Proc Natl Acad Sci U S A. 2005; 102: 16368-16373
- Circulating mutant DNA to assess tumor dynamics.Nat Med. 2008; 14: 985-990
- Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.Sci Transl Med. 2012; 4: 136ra68
- Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.Genome Res. 2012; 22: 220-231
- Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer Res. 1999; 59: 67-70
- Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.Cancer Res. 1999; 59: 71-73
- Prediction of breast tumor progression by integrity of free circulating DNA in serum.J Clin Oncol. 2006; 24 (10): 4270-4276
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.Nat Med. 2014; 20: 548-554
- Direct detection of early-stage cancers using circulating tumor DNA.Sci Transl Med. 2017; 9: eaan2415
- Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discov. 2016; 6: 479-491
- Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.Cancer Discov. 2014; 4: 650-661
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature. 2017; 545 (26): 446-451
- Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science. 2018; 359: 926-930
- Detection of cancer DNA in plasma of early stage breast cancer patients.Clin Cancer Res. 2014; 20: 2643-2650
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer.N Engl J Med. 2013; 368: 1199-1209
- Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer.Gastroenterology. 2020; 158 (1): 494-505
- Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.Cancer Res. 2019; 79: 913
- Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.Clin Cancer Res. 2012; 18: 3462-3469
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med. 2015; 7: 302ra133
- Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.Clin Cancer Res. 2019; 25: 4255-4263
- Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.Sci Rep. 2020; 10: 14704
- Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review.Ann Transl Med. 2020; 8: 1603
Wongchenko MJ, Lipson D, Clark T, Kennedy M, Greene M, Breese V et al. Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC). ORAL PRESENTATIONS - PROFFERED ABSTRACTS| 2018.
- An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).J Immunother Cancer. 2019; 7: 72
- Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).J Clin Oncol. 2019; 37 (10.1200): 2542
- Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer. preplanned secondary analysis of the BRE12-158 randomized clinical trial.JAMA Oncol. 2020; 6: 1410-1415
- Assessment of molecular relapse detection in early-stage breast cancer.JAMA Oncol. 2019; 5: 1473-1478
- Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.ESMO Open. 2021; 6100086
- Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.Front Oncol. 2021; 11736769
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Annals of Oncology. 2021; 32: 229-239
- The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer.Oncol Lett. 2021; 21: 420
- POSTER SPOTLIGHT SESSION ABSTRACTS| 2021. Abstract PD15-06: Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: correlative analysis from clinical trial BRE12-158.Cancer Res. 2021; 81 (PD15-06)
- The emerging role of circulating tumor DNA in the management of breast cancer.Cancers (Basel). 2021; 13: 3813
- Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance.EBioMedicine. 2018; 32: 111-118
- Leptomeningeal metastasis: clinical experience of 519 cases.Eur J Cancer. 2016; 56: 107-114
- Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.Clin Cancer Res. 2022; 28: 1180-1191
- Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.Mol Genet Genomic Med. 2020; 8: e1079
- Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131.J Clin Oncol. 2021; 39: 2539-2551
- Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial.JAMA Oncol. 2021; 7: 1654-1663
- Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res. 2007; 13: 4429-4434
- Pattern of metastatic spread in triple-negative breast cancer.Breast Cancer Res Treat. 2009; 115: 423-428
Article info
Publication history
Published online: March 01, 2023
Accepted:
February 26,
2023
Received in revised form:
January 23,
2023
Received:
August 31,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Inc.
